Magenta Therapeutics' Shares Gain As FDA Signs Off Blood Cancer Candidate To Enter Human Trial

  • The FDA has signed off Magenta Therapeutics Inc's MGTA IND application for MGTA-117.
  • Related Content: Magenta Therapeutics Stock Drops As FDA Issues Clinical Hold On Blood Cancer Candidate IND.
  • The Company expects to open the Phase 1/2 trial in Q4 2021 to evaluate its MGTA-117 antibody-drug conjugate (ADC) targeted conditioning program.
  • The Phase 1/2 trial with single-dose escalating cohorts will evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of MGTA-117 as monotherapy in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) patients. 
  • Magenta will continue to engage with the FDA to transition the trial to the intended primary target population of hematopoietic stem cell transplant-eligible AML and MDS patients. 
  • In addition, Magenta has planned gene therapy trial collaborations with Avrobio Inc AVRO and Beam Therapeutics Inc BEAM to evaluate MGTA-117 for conditioning gene therapy patients without using non-selective busulfan or other toxic chemotherapies.
  • Related content: Benzinga's Full FDA Calendar.
  • Price Action: MGTA shares are up 9.95% at $6.74 during the market session on the last check Wednesday.

Posted In: acute myeloid leukemiaBriefsmyelodysplastic syndromePhase 1 TrialBiotechLong IdeasNewsHealth CareContractsSmall CapMoversTrading IdeasGeneral

Ad Disclosure: The rate information is obtained by Bankrate from the listed institutions. Bankrate cannot guaranty the accuracy or availability of any rates shown above. Institutions may have different rates on their own websites than those posted on Bankrate.com. The listings that appear on this page are from companies from which this website receives compensation, which may impact how, where, and in what order products appear. This table does not include all companies or all available products.

All rates are subject to change without notice and may vary depending on location. These quotes are from banks, thrifts, and credit unions, some of whom have paid for a link to their own Web site where you can find additional information. Those with a paid link are our Advertisers. Those without a paid link are listings we obtain to improve the consumer shopping experience and are not Advertisers. To receive the Bankrate.com rate from an Advertiser, please identify yourself as a Bankrate customer. Bank and thrift deposits are insured by the Federal Deposit Insurance Corp. Credit union deposits are insured by the National Credit Union Administration.

Consumer Satisfaction: Bankrate attempts to verify the accuracy and availability of its Advertisers' terms through its quality assurance process and requires Advertisers to agree to our Terms and Conditions and to adhere to our Quality Control Program. If you believe that you have received an inaccurate quote or are otherwise not satisfied with the services provided to you by the institution you choose, please click here.

Rate collection and criteria: Click here for more information on rate collection and criteria.